Cis-platinum in the treatment of advanced or recurrent adenocarcinoma of the ovary. A phase II study of the Gynecologic Oncology Group.
Thirty-seven patients with advanced or recurrent adenocarcinoma of the ovary no longer amenable to control with surgery, radiation therapy, or higher prior chemotherapy were treated with cis-platinum, 50 mg/m2 intravenously every 3 weeks. Among the 37 patients, three patients had a clinical complete response (8%) and six had a partial response (16%). Twenty-three demonstrated stable disease (62%), while five demonstrated rapidly increasing disease (14%). Median response duration was 5 months and median survival was 10+ months. Responders survived longer than nonresponders (p = 0.01). Adverse effects included leukopenia (26/37), thrombocytopenia (19/37), nausea and vomiting (35/37), and azotemia (19/37). Adverse effects were generally mild to moderate and tolerable. Cis-platinum thus appears to be highly active in the treatment of adenocarcinoma of the ovary at the dose and schedule tested.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D007970:Leukopenia / Q000139:chemically induced; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009364:Neoplasm Recurrence, Local; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D013921:Thrombocytopenia / Q000139:chemically induced; D014839:Vomiting / Q000139:chemically induced
D002945:Cisplatin